World Cup Ticket Pricing Destroys the Atmosphere

FIFA priced the World Cup like the Super Bowl, ignoring that players describe the Super Bowl's atmosphere as "a corporate dinner party." The strategy designed to capture value is now eroding the very asset that creates it. The lesson applies far beyond soccer.

Why the obvious fix creates empty rows

The World Cup starts tomorrow, and nearly 180,000 tickets remain unsold on official resale platforms. That number alone is embarrassing, but what makes it revealing is the causal chain FIFA set in motion. They treated ticketing as a pure revenue extraction problem, not an atmosphere cultivation problem.

FIFA changed everything about ticketing for this tournament: dynamic pricing, prices more than double those in Qatar 2022, and roughly four times what the 1994 US World Cup cost after inflation. The logic seemed straightforward: North Americans are used to paying premium prices for premium experiences. The Super Bowl's cheapest ticket was $900 this year. The Champions League final's was about $200. FIFA looked at that gap and saw an opportunity.

But here is where the systems thinking breaks down. FIFA president Gianni Infantino argued that "no one complains about ticket prices when you go to a concert or an NFL game." That is true only if you ignore what happens to the experience when only the wealthy can attend.

"The Super Bowl has a horrible vibe inside because it's mostly just very, very rich people and corporations that can actually afford those seats."

-- Neal Friman

The immediate effect of high prices is revenue. The second-order effect is a transformed audience. The third-order effect, the one that compounds, is an atmosphere that players themselves describe as flat. Joe Burrow did not say the Super Bowl feels like a dinner party because the nachos were good. He said it because the crowd does not react like a crowd. They are there for the business meeting.

FIFA made a bet that the North American market would absorb any price because demand was supposedly insatiable. Remember those initial numbers? Five hundred million ticket requests, FIFA claimed. But now that we see 180,000 tickets still available, one of those figures was misleading, and it was not the unsold tickets. The host puts it directly: "It looks like they were lying about the initial demand."

The system is already responding. Resale prices have dropped 20% in the past month. After accounting for FIFA's 26% transaction fee, most resellers are now taking a loss. The people who bought early thinking they could scalp are getting burned. TV cameras are about to pan to rows of empty seats at the most expensive World Cup in history.

This is what happens when you optimize for maximum extraction without modeling system pushback: the product degrades, the brand erodes, and the thing you tried to capture value from becomes less valuable.

The sunscreen regulatory bottleneck: how America fell two decades behind

On a completely different scale, the FDA just approved its first new sunscreen ingredient in nearly thirty years. The molecule, BEMT (Bemotrizinol), has been used in Europe since 1999 and across Asia for just as long. The United States is finally catching up.

The insight here is not about the molecule itself, which provides broad-spectrum UVA and UVB protection without the white residue mineral sunscreens leave behind. It is about how regulatory classification creates downstream consequences that compound over decades.

In the US, sunscreen is regulated as an over-the-counter drug. That means every active ingredient requires human clinical trials to prove safety. In Europe, sunscreen is a cosmetic. The result: Europe has 29 approved UV filters. The US had 16. Now 17. That gap is no accident; it is structural.

The downstream effects are measurable and ironic. Because the FDA dragged its feet over concerns that chemical ingredients could enter the bloodstream, Americans got worse sunscreen options for decades. Moreover, a survey found that in 2021, 17% of Americans believed sunscreen was toxic. By 2025, that number had risen to 24%. The regulatory caution may have inadvertently fueled the very distrust it was trying to prevent.

"The FDA has been dragging its feet on giving it the okay in America over fears that chemical sunscreen ingredients could enter the bloodstream."

-- Neal Friman

BEMT dodges those concerns. Clinical data shows it is not easily absorbed, but the damage from the regulatory vacuum has already been done. A decade of worse products, declining public trust, and a thriving market for misinformation.

The structural lesson: when you regulate for perfect safety, you do not just delay innovation. You create the conditions for skepticism and alternatives that may be far less safe.

The longevity paradox: why the most promising science comes from the most controversial scientists

Life Biosciences just injected the first patient with a treatment designed to reverse cellular aging. It is a tiny trial, just 18 participants targeting glaucoma in one eye, but it represents a genuine breakthrough in partial cellular reprogramming.

The science is clever. Scientists have known for years how to reset adult cells to an embryonic-like state using four Yamanaka factors. But full resetting erases cellular identity and risks cancer. The trick Life Biosciences uses is partial reprogramming: using only three of the four factors, skipping the one most associated with cancer, and including an off-switch.

But the more interesting dynamic is the tension around the field's leading figure. David Sinclair, co-founder of Life Biosciences, has made ambitious claims about longevity. He said, "the person who's going to live to 150 has already been born." Some former colleagues have called him a snake oil salesman. Yet multiple sources acknowledge that whatever progress is happening in this space "could not have happened without him."

This is the pattern: breakthrough science often requires someone willing to over-claim publicly while under-delivering privately. The hype attracts capital and talent. The hype also attracts criticism. The question is whether the actual science, this tiny trial of 18 patients, can justify the ambition. The patient will be monitored for six months. If it works in one eyeball, it opens the door to liver, muscle, brain, the rest of the body.

The time horizon matters here. This is not a 12-month pay-off. It is a decade-long investment that may or may not justify the hype. But the only way to find out is to run the experiment, which requires exactly the kind of outlandish boosterism that makes serious scientists uncomfortable.

Key action items

• If you are pricing an experience, map the atmosphere consequences. Before setting prices, ask: who gets priced out, and does their absence degrade the product for everyone? This matters for events, yes, but also for subscription tiers, community access, and any product where the audience is part of the experience.
• Check your regulatory assumptions for hidden lag. If you operate in a heavily regulated industry, ask whether your regulatory classification makes sense or just inherited inertia. The sunscreen lesson: cosmetic vs. drug classification created a two-decade gap in consumer protection.
• Watch the unsold ticket signal for broader market softening. 180,000 unsold World Cup tickets is not just a FIFA problem. It may indicate that premium experience pricing has hit a ceiling across entertainment and live events.
• Over the next quarter: read sunscreen ingredient labels and understand the difference between UVA and UVB protection. Most US sunscreens are good at preventing burns (UVB) but weak against aging and deeper damage (UVA). BEMT products will not be widely available for 15-18 months (patent exclusivity), but knowing the gap exists changes purchase decisions now.
• This pays off in 12-18 months: build partial-reprogramming thinking into your R&D pipeline. The longevity field's insight (reset cells partially, not fully) applies broadly. In software, do not rewrite the whole system. In teams, do not restructure everything. Find the three factors that matter and skip the fourth that causes chaos.
• The uncomfortable advantage: embrace the messenger you disagree with. Sinclair is controversial. He also moved the field. Before dismissing a difficult person, ask: is their contribution separable from their personality? Often it is not, and that is the price of progress.
• For event planners: build resale market dynamics into your pricing model. FIFA assumed demand was fixed. It was not. If you are selling tickets or access of any kind, model what happens when secondary markets crack. That is where the real signal lives.